Initiator Pharma A/SOMXSTO: INIT

Initiator Pharma To Fully Prioritize Pudafensine

· Issued by Initiator Pharma A/S

On 6ix: 6ix.com/news/initiator-pharma-to-fully-prioritize-pudafensine

Initiator Pharma A/S OMXSTO:INIT:

  • INITIATOR PHARMA TO FULLY PRIORITIZE PUDAFENSINE

  • TO FOCUS FULLY ON ITS MOST PROMISING DRUG CANDIDATE, PUDAFENSINE

  • WILL DISCONTINUE FURTHER DEVELOPMENT OF IP2018

  • RESOURCES FROM IP2018 TO BE REDIRECTED TO PUDAFENSINE DEVELOPMENT

  • PUDAFENSINE PHASE IIA STUDY IN VULVODYNIA EXPECTED TO COMPLETE BY END 2026

  • ADDITIONAL PROOF-OF-CONCEPT DATA IN VULVODYNIA EXPECTED BEFORE YEAR-END

Initiator Pharma A/S on 6ix

Earlier from Initiator Pharma

Later from Initiator Pharma

All Initiator Pharma news releases